NDDS in Cancer Therapy - Global Market Trajectory & Analytics

Global NDDS in Cancer Therapy Market to Reach $25.5 Billion by 2027

Amid the COVID-19 crisis, the global market for NDDS in Cancer Therapy estimated at US$7.3 Billion in the year 2020, is projected to reach a revised size of US$25.5 Billion by 2027, growing at a CAGR of 19.7% over the period 2020-2027. Embolization Particles, one of the segments analyzed in the report, is projected to record 21% CAGR and reach US$1.9 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Nanoparticles segment is readjusted to a revised 19.6% CAGR for the next 7-year period.



The U.S. Market is Estimated at $2.2 Billion, While China is Forecast to Grow at 19.3% CAGR

The NDDS in Cancer Therapy market in the U.S. is estimated at US$2.2 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$4.5 Billion by the year 2027 trailing a CAGR of 19.3% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 17.5% and 16.7% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 13.8% CAGR.

Select Competitors (Total 46 Featured):

• Celgene Corporation
• Galen Limited
• Merrimack Pharmaceuticals, Inc.
• Samyang Biopharmaceuticals Corp.
• Spectrum Pharmaceuticals
• Teva Pharmaceutical Industries Ltd.